Want to see APYX full AI Analyst Report?
APYX Stock Chart & Stats
$3.13
-$0.11(-6.43%)
At close: 4:00 PM EST
$3.13
-$0.11(-6.43%)
Day’s Range― - ―
52-Week Range$1.59 - $5.08
Previous CloseN/A
Volume28.06K
Average Volume (3M)120.72K
Market Cap
$188.43M
Enterprise Value$184.61M
Total Cash (Recent Filing)$31.14M
Total Debt (Recent Filing)$39.46M
Price to Earnings (P/E)―
Beta1.86
Next Earnings
Aug 06, 2026EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.22
Shares Outstanding41,873,950
10 Day Avg. Volume65,017
30 Day Avg. Volume120,723
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)10.15
Price to Sales (P/S)2.79
P/FCF Ratio-16.19
Enterprise Value/Market Cap0.98
Enterprise Value/Revenue3.30
Enterprise Value/Gross Profit10.23
Enterprise Value/Ebitda-75.57
Forecast
1Y Price Target
$6.00Price Target Upside91.69% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.28
Revenue Forecast (FY)$59.56M
Bulls Say, Bears Say
Bulls Say
Recurring Consumables (razor-and-blades)Apyx’s razor-and-blades model aligns capital equipment placements with recurring disposable sales, creating a durable revenue stream tied to procedure volume. As installed base and procedure adoption grow, consumable frequency provides predictable, higher-margin follow-on revenue supporting long-term margin and cash generation.
Regulatory Expansion For AYONThe AYON power-liposuction clearance is a structural product expansion that broadens the system’s capabilities and addressable market. By consolidating multiple modalities into one platform, Apyx can accelerate unit adoption, increase consumable usage per procedure, and strengthen its competitive position in surgical aesthetics over the next several quarters.
Material Debt Reduction And Cash RunwaySharp deleveraging and a multi‑quarter cash runway materially improve financial flexibility. Lower leverage reduces insolvency risk and interest burden, enabling disciplined reinvestment in AYON commercialization and international registrations without immediate reliance on dilutive capital, supporting sustainable execution over the medium term.
Bears Say
Negative Operating And Free Cash FlowPersistent negative operating and free cash flow means the business still consumes cash despite improved trends. Continued cash burn limits ability to scale commercial investment without external funding, increasing dependency on capital markets or dilution and constraining sustainable margin conversion until cash generation turns positive.
Ongoing GAAP Losses And Negative MarginsAlthough losses narrowed, GAAP profitability remains elusive with negative operating and net margins. Until Apyx sustains positive EBIT and net income, reinvestment must be balanced against cost control, and investors face execution risk that margins may not normalize to durable levels implied by management guidance.
Adoption And International Rollout UncertaintyCommercial growth depends on surgeon adoption and staggered international registrations. Early-stage domestic uptake and long, variable regulatory timelines abroad mean revenue realization is timing‑dependent. Execution risk around training, workflow integration, and registration pacing could delay durable installed‑base expansion and recurring consumable demand.
Apyx Medical News
APYX FAQ
What was Apyx Medical Corporation’s price range in the past 12 months?
Apyx Medical Corporation lowest stock price was $1.59 and its highest was $5.08 in the past 12 months.
What is Apyx Medical Corporation’s market cap?
Apyx Medical Corporation’s market cap is $188.43M.
When is Apyx Medical Corporation’s upcoming earnings report date?
Apyx Medical Corporation’s upcoming earnings report date is Aug 06, 2026 which is in 38 days.
How were Apyx Medical Corporation’s earnings last quarter?
Apyx Medical Corporation released its earnings results on May 07, 2026. The company reported -$0.05 earnings per share for the quarter, beating the consensus estimate of -$0.11 by $0.06.
Is Apyx Medical Corporation overvalued?
According to Wall Street analysts Apyx Medical Corporation’s price is currently Undervalued.
Does Apyx Medical Corporation pay dividends?
Apyx Medical Corporation does not currently pay dividends.
What is Apyx Medical Corporation’s EPS estimate?
Apyx Medical Corporation’s EPS estimate is -0.09.
How many shares outstanding does Apyx Medical Corporation have?
Apyx Medical Corporation has 41,873,950 shares outstanding.
What happened to Apyx Medical Corporation’s price movement after its last earnings report?
Apyx Medical Corporation reported an EPS of -$0.05 in its last earnings report, beating expectations of -$0.11. Following the earnings report the stock price went up 21.918%.
Which hedge fund is a major shareholder of Apyx Medical Corporation?
Currently, no hedge funds are holding shares in APYX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Apyx Medical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.00 (91.69% Upside)
$6.00 (91.69% Upside)
Hedge Fund Trend
Increased
By 168.2K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Positive
20 days / 200 days
Momentum
129.93%
12-Months-Change
Fundamentals
Return on Equity
-90.62%
Trailing 12-Months
Asset Growth
4.76%
Trailing 12-Months
Company Description
Apyx Medical Corporation
Apyx Medical Corporation, an energy technology company, designs, develops, manufactures, and sells electrosurgical equipment and medical devices in the United States and internationally. The company operates through two segments: Surgical Aesthetics and Original Equipment Manufacturing (OEM). It offers helium plasma generator for the delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures; and a portfolio of single-use handpieces and accessories for open and laparoscopic procedures. The company’s helium plasma technology products are marketed and sold under the Renuvion name in the cosmetic surgery market and under the J-Plasma name in the hospital surgical market. It also develops and manufactures OEM generators and related accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.
APYX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed substantial positive operational and financial momentum driven by the AYON commercial launch and strong Surgical Aesthetics demand: double-digit revenue growth, expanding gross margins, reduced operating losses, improved adjusted EBITDA, a raised full-year revenue guide, and a healthy cash balance with a runway into 2027. Offsetting risks include a remaining GAAP net loss, tariff-related cost pressure, an expected long-term decline in the OEM business, some domestic generator sales decline/reclassification, and adoption timing dependency on the forthcoming power-liposuction label and international registrations. Overall, the positives—particularly the robust AYON ramp, international traction, margin expansion, and upgraded guidance—significantly outweigh the negatives.View all APYX earnings summariesAPYX Stock 12 Month Forecast
Average Price Target
$6.00
▲(91.69% Upside)
Technical Analysis
Ownership Overview
6.80% Insiders
8.89% Mutual Funds
35.47% Other Institutional Investors
45.05% Public Companies and
Individual Investors